Biogen Inc. (NASDAQ:BIIB)

Stock Price: $197.78
-2.84 (-1.42%)
Updated Sep 23, 2022 08:00 PM GMT+0000
Featured app
eToro review
Invest now
68% of retail CFD accounts lose money
Overview
Financials
Statistics
Chart
Market Cap 28.70B
Revenue 10.63B
Gross Profit 8.22B
Shares Out 145.11M
EPS (ttm) 13.97
PE Ratio 13.9377
Forward PE 12.0023
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Sep 23
Last Price $197.78
Previous Close $200.62
Change ($) -2.84
Change (%) -1.42%
Day's Open 200.28
Day's Range 194.45 - 200.99
Day's Volume 1.44M
52 Week Range 187.16 - 291.54

About Biogen Inc.

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.

One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

News

Quick info

Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
9,100
CEO
Michel Vounatsos
Address
225 Binney St
Cambridge
Massachusetts
02142-1031
Phone
17814642000
Website
www.biogen.com
Ticker Symbol
BIIB
Reporting Currency
USD